SCHOTT Pharma AG & Co KgaA reported first quarter 2026 results that exceeded expectations, with sales reaching €240 million, up 4.8% at constant exchange rates compared to the same period last year. The German pharmaceutical services company posted an EBITDA of €65.2 million for the quarter, resulting in a margin of 27.1%, above consensus estimates of 26.3%.

High-value solutions (HVS) accounted for 57% of total sales, maintaining the strong trajectory seen in fiscal year 2025. The Drug Containment Solutions (DCS) segment showed robust performance with revenues increasing 9.4% at constant exchange rates to €137 million, driven by sterile cartridges for biologics and GLP-1 treatments, as well as specialty vials for ADC therapies. The segment's EBITDA grew 18.9% to €33.4 million, with margin expanding to 24.3% from 21.9% in Q1 2025.

The Drug Delivery Systems (DDS) segment saw revenues remain relatively flat, decreasing 0.8% at constant exchange rates to €103 million. Despite ongoing market uncertainties, management reaffirmed its full-year 2026 guidance, projecting organic revenue growth of approximately 2-5% at constant exchange rates and an EBITDA margin of around 27%. The company also announced that Christian Mias will succeed Andreas Reisse as CEO, effective May 1, 2026.